PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer (PCOX)

Sun Yat-sen University logo

Sun Yat-sen University

Status and phase

Phase 2


Colorectal Cancer


Drug: PD-1 antibody + cox inhibitor

Study type


Funder types




Details and patient eligibility


PD-1(programmed death protein 1)antibody has been to approved in patients with MSI-H/dMMR advanced cancer and has achieved significant efficacy. It is reported that the objective response rate of Pembrolizumab and Nivolumab are 40% and 31.1% in MSI-H/dMMR (microsatellite instability-high/deficiency mismatch repair )colorectal cancer. What's more, most of the patients who had response for PD-1 antibody achieved a long duration of disease control. However, not all patients with MSI-H/dMMR was sensitive to PD-1 antibody despite it is a biomarker for PD-1 antibody treatment. There were about 50-60% of patients with MSI-H/dMMR were insensitive and we don't know why. What's more, it's reported that tumor mutation burden (TMB) may be another biomarker of response to PD-1 therapy. COX (cyclooxygenase)inhibitor has been proved to prevent adenomas in colorectal and it is safe for most of the patients. Preclinical models also showed that COX inhibitor could act with PD-1 antibody in mice and control disease progress. So, this study aims to evaluated efficacy and safety of combination of PD-1 antibody and COX inhibitor in patients with MSI-H/dMMR or high tumor mutation burden colorectal cancer.

Full description

This is a single arm, phase two study. Eligible patients with advanced MSI-H/dMMR colorectal cancer were assigned to receive BAT1306 plus COX inhibitor. All patients will receive the study regimen every 3 weeks. Chest/abdomen/pelvic CT with IV contrast will be performed to assess clinical response.


29 estimated patients




18 to 80 years old


No Healthy Volunteers

Inclusion criteria

  • Signed informed consent; able to comply with study and/or follow- up procedures;
  • Age:18-75 years old;
  • Histological or cytological documentation of colorectal cancer;
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
  • There must be documentation by CT scan, MRI, or intraoperative palpation that tumor is unresectable;
  • Have had at least one lines of chemotherapy fail or refuse to receive chemotherapy;
  • Histologically confirmed metastatic or primary colorectal cancer as dMMR/MSI-H or whole exon sequence confirmed tumor mutation burden higher than 1000;
  • Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: Hemoglobin (Hb) ≥ 90g/ L, absolute neutrophil count (ANC) ≥ 1.5×109/ L, platelet count ≥ 100×109/ L; Total bilirubin ≤ 1.5×the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 ×ULN; Serum creatinine ≤1.5×the ULN.

Exclusion criteria

  • Previous treatment with other therapy targeting T-cell costimulation or immune checkpoint pathways;
  • Active, known, or suspected autoimmune disease (except for type 1 diabetes mellitus, residual hypothyroidism due to autoimmune condition requiring only hormone replacement, or conditions not expected to recur in the absence of an external trigger);
  • A previous cancer active within the previous 5 years;
  • Subjects with known allergy to the study drugs or to any of its excipients;
  • Significant cardiovascular disease including unstable angina or myocardial infarction within 6 months before initiating study treatment;
  • Heart failure grade III/IV (NYHA-classification);
  • Patients with active infection within 1 week before enrollment (infection caused by fever above 38 °C);
  • Patients with severe lung disease (interstitial pneumonia, pulmonary fibrosis, severe emphysema);
  • Patients with active gastrointestinal bleeding;
  • Patients with serious complications (intestinal obstruction, renal insufficiency, hepatic insufficiency, cerebrovascular disorders);
  • Psychiatric disease or a history of central nervous system disease that affects clinical treatment;
  • Receive other anti-tumor treatments (including anti-tumor immunotherapy, interventional therapy and intra-serosal injection of anti-tumor drugs) or participate in other interventional clinical trials within two weeks before enrollment;
  • Breast- feeding or pregnant women;
  • Lack of effective contraception;
  • The investigator determined that the patient was not eligible for this clinical trial.

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

29 participants in 1 patient group

PD-1 antibody + cox inhibitor
Experimental group
BAT1306 + aspirin(celebrex when there is contraindication to aspirin) on day 1-21 every three weeks
Drug: PD-1 antibody + cox inhibitor

Trial contacts and locations



Central trial contact

Yanhong Deng, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems